1-20 of 52
Jeffrey Matous
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with Relapsed/Refractory multiple myeloma

Free
Amrita Krishnan, Martin Kaiser, Rakesh Popat, Jeffrey Matous, Alfred Garfall, Gala Vega, Aurore Perrot, Sébastien Anguille, Albert Oriol, Nicolas Kint, Jo Caers, Saad Usmani, Lionel Karlin, Larysa Sanchez, Cindy Varga, Wilfried Roeloffzen, Laura Rosiñol Dachs, Darren Pan, Paula Rodriguez-Otero, María-Victoria Mateos, Tadao Ishida, Kentaro Fukushima, Pansy Minnick, M. Damiette Smit, Nikki Daskalakis, Thomas Prior, Deeksha Vishwamitra, Emily DeSantis, Ashley Nguyen, Brandi Hilder, Joseph Weidman, Caroline Hodin, Daniel Jonathan, Sangmin Lee, Cyrille Touzeau, Hans Lee, Niels W.C.J. Van De Donk, Monique Minnema
Journal: Blood
Blood (2025) 146 (Supplement 1): 4042.
https://doi.org/10.1182/blood-2025-4042
Published: 2025
Journal Articles

Immune population dynamics predict multiple myeloma progression while on daratumumab maintenance therapy following autologous stem cell transplant

Free
Ryan Woodall, Alexander Pozhitkov, Azra Borogovac, Theophilus Tandoh, Alexander Brummer, Vikram Adhikarla, James Sanchez, Hearn Cho, Jeffrey Matous, Jesús Berdeja, Amrita Krishnan, Russell Rockne, Flavia Pichiorri
Journal: Blood
Blood (2025) 146 (Supplement 1): 7451.
https://doi.org/10.1182/blood-2025-7451
Published: 2025
Journal Articles

Talquetamab, a GPRC5D×CD3 bispecific antibody, in combination with pomalidomide in patients with Relapsed/Refractory multiple myeloma: Updated safety and efficacy results from the Phase 1b monumental-2 study

Free
Hang Quach, Aurore Perrot, Jeffrey Matous, Noa Biran, Jesús Berdeja, Kathleen Dorritie, Janine Elssen, Cyrille Touzeau, Sébastien Anguille, Gurdeep Parmar, Andrew Spencer, Nicolas Kint, Cyrille Hulin, Kevin Boyd, Rakesh Popat, Wouter Plattel, Attaya Suvannasankha, Ashwini Rachamalla, Ashley Nguyen, Diana Cortes-Selva, Michela Campagna, Tara Masterson, Veronique Vreys, Paula Barreyro, Gary Mason, Thomas Renaud, Dr. Emma Searle
Journal: Blood
Blood (2025) 146 (Supplement 1): 2282.
https://doi.org/10.1182/blood-2025-2282
Published: 2025
Journal Articles

Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up

Free
Saad Usmani, Shaji Kumar, María-Victoria Mateos, J Christine Ye, Shebli Atrash, Hila Magen, Hang Quach, Michael Chu, Suzanne Trudel, Joshua Richter, Paula Rodriguez-Otero, Hun Chuah, Moshe Gatt, Eva Medvedova, Shahzad Raza, Dok Hyun Yoon, Tadao Ishida, Jeffrey Matous, Laura Rosiñol Dachs, Koichi Onodera, Carmela Maffucci, Emma Scott, Christoph Heuck, Jing Zhang, Todd Henninger, Lisa O'Rourke, Payal Thakkar, Mariacristina Festa, Lin Huang, Jiangxiu Zhou, Mikihiro Takamoto, Lixia Pei, Jiashen Lu, Nicholas Au, Maria Krevvata, Yaël Cohen
Journal: Blood
Blood (2025) 146 (Supplement 1): 698.
https://doi.org/10.1182/blood-2025-698
Published: 2025
Journal Articles

Results of the Phase II d-PRISM study: Daratumumab in high-risk MGUS and low-risk smoldering myeloma

Free
Omar Nadeem, Michelle Aranha, Robert Redd, Michael Koontz, Jeffrey Matous, Andrew Yee, Jeffrey Zonder, Andrew Kin, Sophie Magidson, Elizabeth Lightbody, Ting Wu, Floris Chabrun, Jean-Baptiste Alberge, Ankit Dutta, Jacqueline Perry, Ashlee Sturtevant, Mahshid Rahmat, Junko Tsuji, Christine Davie, Caroline Ricciardi, Frances Arters, Marjorie Marto, Amy Goguen, Jacalyn Rosenblatt, Elizabeth O'Donnell, Jacob Laubach, Paul Richardson, Gad Getz, Lorenzo Trippa, Romanos Sklavenitis-Pistofidis, Irene Ghobrial
Journal: Blood
Blood (2025) 146 (Supplement 1): 1533.
https://doi.org/10.1182/blood-2025-1533
Published: 2025
Journal Articles

Talquetamab + Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study

Free
Jeffrey Matous, Noa Biran, Aurore Perrot, Jésus G Berdeja, Kathleen Dorritie, Janine Van Elssen, Emma Searle, Cyrille Touzeau, Sébastien Anguille, Deeksha Vishwamitra, Ashley Nguyen, Debopriya Ghosh, Elizabeth Shearin, Katherine Thornton, Damiette Smit, Hang Quach
Journal: Blood
Blood (2023) 142 (Supplement 1): 1014.
https://doi.org/10.1182/blood-2023-187706
Published: 2023
Journal Articles

Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Free
Prashant Kapoor, Don A. Stevens, Xavier Leleu, Karim Belhadj Merzoug, Lionel Karlin, Salomon Manier, Thomas Chalopin, Cyrille Hulin, Aurore Perrot, Jésus G Berdeja, Cristiana Costa Chase, Cyrille Touzeau, Philippe Moreau, Sanjay Mohan, Alexander Lesokhin, Carol Huff, David H. Vesole, Joshua Richter, Jeffrey Matous, Eileen Wolff, Tejas Shah, Jeppe Koch-Olsen, Andrew Garton, Vinu Menon, Sunitha Gn, Mario Perro, Eugene Zhukovsky, Cyril Konto, Lida Pacaud, Mohamad Mohty
Journal: Blood
Blood (2023) 142 (Supplement 1): 3339.
https://doi.org/10.1182/blood-2023-186664
Published: 2023
Journal Articles

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

Free
Clinical Trials & Observations
Ann S. LaCasce, R. Gregory Bociek, Ahmed Sawas, Paolo Caimi, Edward Agura, Jeffrey Matous, Stephen M. Ansell, Howland E. Crosswell, Miguel Islas-Ohlmayer, Caroline Behler, Eric Cheung, Andres Forero-Torres, Julie Vose, Owen A. O’Connor, Neil Josephson, Yinghui Wang, Ranjana Advani
Journal: Blood
Blood (2018) 132 (1): 40–48.
https://doi.org/10.1182/blood-2017-11-815183
Published: 2018
Includes: Supplemental data
Journal Articles

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma

Free
Clinical Trials & Observations
Barbara Pro, Ranjana Advani, Pauline Brice, Nancy L. Bartlett, Joseph D. Rosenblatt, Tim Illidge, Jeffrey Matous, Radhakrishnan Ramchandren, Michelle Fanale, Joseph M. Connors, Keenan Fenton, Dirk Huebner, Juan M. Pinelli, Dana A. Kennedy, Andrei Shustov
Journal: Blood
Blood (2017) 130 (25): 2709–2717.
https://doi.org/10.1182/blood-2017-05-780049
Published: 2017
Includes: Supplemental data
Journal Articles

Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Free
Barbara Pro, MD, Ranjana H Advani, MD, Pauline Brice, MD, Nancy L Bartlett, MD, Joseph D Rosenblatt, MD, Tim Illidge, PhD, Jeffrey Matous, MD, Radhakrishnan Ramchandren, MD, Michelle A Fanale, MD, Joseph M. Connors, Keenan Fenton, Dirk Huebner, MD, Juan Pinelli, Andrei R. Shustov
Journal: Blood
Blood (2016) 128 (22): 4144.
https://doi.org/10.1182/blood.V128.22.4144.4144
Published: 2016
Journal Articles

A Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Final Analysis of Second Dose Expansion

Free
Jesus G. Berdeja, MD, Tara B. Gregory, MD, Edward Faber, Jeffrey Matous, MD, Lowell Hart, MD, Joseph R. Mace, MD, Edward R. Arrowsmith, MD MPH, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4530.
https://doi.org/10.1182/blood.V128.22.4530.4530
Published: 2016
Journal Articles

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Free
Irene M. Ghobrial, MD, Ashraf Z Badros, MD, James J. Vredenburgh, MD, Jeffrey Matous, MD, Aaron M. Caola, BS, Alexandra Savell, Patrick Henrick, Claudia E. Paba-Prada, MD, Robert L. Schlossman, MD, Jacob P. Laubach, MD, Jacalyn Rosenblatt, MD, Andrew Yee, Jeffrey S. Wisch, MD, Charles M. Farber, MD PhD, Rodrigo O. Maegawa, MD, Saad Z Usmani, MD FACP, Joseph Cappuccio, Bradley Rivotto, BS, Kimberly Noonan, NP, Kaitlen Reyes, DNP, Nikhil C. Munshi, MD, Kenneth C. Anderson, Paul Richardson, MD
Journal: Blood
Blood (2016) 128 (22): 976.
https://doi.org/10.1182/blood.V128.22.976.976
Published: 2016
Journal Articles

Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study)

Free
Ruben Niesvizky, MD, Paul G. Richardson, MD, Andrew J. Yee, MD, Ajay K Nooka, Marc S Raab, Kenneth H. Shain, MD PhD, Nashat Y. Gabrail, MD, Jeffrey Matous, MD, Amit B. Agarwal, James Hoffman, MD, Sumit Madan, MD, John M. Pagel, MD PhD, Jesus San Miguel, MD PhD, Philippe Moreau, Maria-Victoria Mateos, MD PhD, Thierry Facon, David Tamang, PhD, Simon S Jones, PhD, Robert J Markelewicz, Jr., MD, Catherine Wheeler, MD, Nikolaus S. Trede, MD PhD, Noopur Raje, MD, Evangelos Terpos, William I. Bensinger, MD
Journal: Blood
Blood (2016) 128 (22): 3307.
https://doi.org/10.1182/blood.V128.22.3307.3307
Published: 2016
Journal Articles

Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study

Free
Ajai Chari, MD, Saurabh Chhabra, MD, Saad Usmani, MD, Sarah Larson, MD, Ruben Niesvizky, MD, Jeffrey Matous, MD, Cristina Gasparetto, MD, Beata Holkova, MD, Matthew Lunning, DO, Jason Valent, MD, Larry D. Anderson, Jr., MD PhD, Chatchada Karanes, MD, Long Kwei, PhD, Lipo Chang, Thorsten Graef, MD PhD, Elizabeth Bilotti, MSN, Kevin McDonagh, MD
Journal: Blood
Blood (2015) 126 (23): 377.
https://doi.org/10.1182/blood.V126.23.377.377
Published: 2015
Journal Articles

Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma

Free
Ann S. LaCasce, MD, Gregory Bociek, Ahmed Sawas, Paolo F. Caimi, MD, Edward Agura, Jeffrey Matous, Stephen Ansell, MD PhD, Howland Crosswell, MD, Miguel Islas-Ohlmayer, Caroline Behler, Eric Cheung, Andres Forero-Torres, Julie Vose, Owen A. O'Connor, MD, Neil Josephson, Ranjana Advani
Journal: Blood
Blood (2015) 126 (23): 3982.
https://doi.org/10.1182/blood.V126.23.3982.3982
Published: 2015
Journal Articles

A Phase I Trial of Pomalidomide, Bortezomib (Velcade), and Dexamethasone (PVD) As Initial Treatment of AL Amyloidosis and Light Chain Deposition Disease

Free
Jeffrey Zonder, MD, Christiane Houde, BS, Sascha Tuchman, MD, Vishal Kukreti, MD, Vaishali Sanchorawala, MD, Silva Pregja, MBA, Kathy A Reichel, Steven M Burt, NP, Colleen Neveux, RN, Jeffrey Matous, MD
Journal: Blood
Blood (2014) 124 (21): 4767.
https://doi.org/10.1182/blood.V124.21.4767.4767
Published: 2014
Journal Articles

MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability of Pomalidomide + Low-Dose Dexamethasone in Patients with Relapsed or Refractory and Refractory Multiple Myeloma and Renal Impairment

Free
Jeffrey Matous, MD, David S Siegel, MD PhD, Sagar Lonial, MD, R. Donald Harvey, PharmD, Claudia Kasserra, PhD, Yan Li, PhD, Min Chen, PhD, Thomas Doerr, MSc, Lars Sternas, MD, Mohamed H. Zaki, MD, Christian Jacques, MD, Jatin J. Shah, MD
Journal: Blood
Blood (2014) 124 (21): 4730.
https://doi.org/10.1182/blood.V124.21.4730.4730
Published: 2014
Journal Articles

A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma

Free
Jacob P. Laubach, MD, Noopur S. Raje, MD, Andrew J. Yee, MD, Philippe Armand, MD PhD, Robert L. Schlossman, MD, Jacalyn Rosenblatt, MD, Jeffrey Matous, MD, Jacquelyn Hedlund, MD, Michael G Martin, MD, Craig Reynolds, MD, Kenneth H. Shain, MD PhD, Ira Zackon, MD, Laura V. Stampleman, MD, Erica N Boswell, BS, Stacey Chuma, BSN, Rebecca Liguori, MS, Stephanie Mar, Damian Handisides, Stew Kroll, Kenneth C. Anderson, MD, Paul G. Richardson, Irene M. Ghobrial, MD
Journal: Blood
Blood (2014) 124 (21): 2142.
https://doi.org/10.1182/blood.V124.21.2142.2142
Published: 2014
Journal Articles

An Open-Label, Phase Ib Study of Duvelisib (IPI-145) in Combination with Bendamustine, Rituximab or Bendamustine/Rituximab in Select Subjects with Lymphoma or Chronic Lymphocytic Leukemia

Free
Ian Flinn, Manish R. Patel, MD, Michael B Maris, MD, Jeffrey Matous, MD, Mohamad Cherry, MD, Jesus G. Berdeja, MD
Journal: Blood
Blood (2014) 124 (21): 4422.
https://doi.org/10.1182/blood.V124.21.4422.4422
Published: 2014
Journal Articles

Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Free
Barbara Pro, MD, Ranjana Advani, MD, Pauline Brice, MD, Nancy L. Bartlett, MD, Joseph D. Rosenblatt, MD, Tim Illidge, Jeffrey Matous, MD, Radhakrishnan Ramchandern, MD, Michelle A. Fanale, MD, Joseph M. Connors, MD, Yinghui Wang, MS, Dirk Huebner, MD, Dana A. Kennedy, PharmD, BCOP, Andrei R. Shustov, MD
Journal: Blood
Blood (2014) 124 (21): 3095.
https://doi.org/10.1182/blood.V124.21.3095.3095
Published: 2014